Mayo Clinic laboratory and pathology research roundup: June 22
The research roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.
Independent reviewers selected studies and extracted data. Meta-analysis was performed with the DerSimonian-Laird random-effects model with Hartung-Knapp-Sidik-Jonkman variance correction or by using a fixed-effect model based on the Mantel-Haenszel method if the number of studies was small. Via JAMA
Published to PubMed This Week
- A molecular pathology, neurobiology, biochemical, genetic and neuroimaging study of progressive apraxia of speech.
- RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis.
- Characteristics and spatially-defined immune (micro)landscapes of early-stage PD-L1-positive triple-negative breast cancer.
Clinical Cancer Research
- Teaching neuroImages: Linear radial periventricular enhancement in glial fibrillary acidic protein astrocytopathy.
- Identification of genetic causes of focal segmental glomerulosclerosis increases with proper patient selection.
Mayo Clinic Proceedings
- Microbiology of hip and knee periprosthetic joint infections: A database study.
Clinical Microbiology and Infections
- Blocking the TSH receptor with K1-70™ in a patient with follicular thyroid cancer, Graves' disease and Graves' ophthalmopathy.
- Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials.
American Journal of Hematology
- Evaluation of self-collected mid-turbinate nasal swabs and saliva for detection of SARS-CoV-2 RNA.
Journal of Clinical Microbiology
- The combination of venetoclax and Ixazomib selectively and efficiently kills HIV-Infected cell lines but has unacceptable toxicity in primary cell models.
Journal of Virology